Zimmer lands FDA clearance for 3-D surgical system

The FDA cleared Zimmer's PSI Shoulder system, which helps place its Trabecular Metal Reverse Shoulder implant (above) during surgery.--Courtesy of Zimmer

In a move that helps bolster Zimmer's ($ZMH) steady growth so far this year, the FDA granted the Indiana musculoskeletal devicemaker clearance for its shoulder system used in reverse implant procedures.

Zimmer's Patient Specific Instruments (PSI) Shoulder system uses 3-D visualization together with the company's Trabecular Metal Reverse Shoulder implant to help create a surgical plan and ease placement of the device, according to the company. With the 3-D view, the PSI Shoulder allows the surgeon to plan out the size and position of the implant within the patient's specific shoulder structure.

The PSI Shoulder has been available in Europe since May, and the Trabecular shoulder implant has been on the market for two years. Zimmer's Trabecular Metal technology, also used in hip and knee implants, is a porous bone implant that supports biologic ingrowth and promotes high friction and stability in the joints, Zimmer said in a release.

"With PSI Shoulder, we present our surgeon customers with a powerful new tool to plan the glenoid side of the surgery with the patient's unique anatomy in full view and functional needs in mind, resulting in a physical reference in the operating room to complete the surgery with confidence," Zimmer Vice President and General Manager Roberto Munoz said in a statement.

Zimmer posted solid growth through the first half of this year with $1.7 billion in net sales, a jump of 4% over the same period last year. But on the surgical device side, the company this month found itself owing $228 million in a patent lawsuit with Stryker ($SYK) over Zimmer's Pulsavac Plus.

- here's the release

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.